Oruka Therapeutics, Inc. Costs and Expenses
Oruka Therapeutics, Inc. (ORKA) reported Costs and Expenses of $2.72 million for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2015-08-11
- Oruka Therapeutics, Inc. costs and expenses for the quarter ending 2015-06-30 was $2.72M, a 13.01% increase year-over-year.
- Oruka Therapeutics, Inc. costs and expenses for the quarter ending 2015-03-31 was $2.74M, a 14.81% increase year-over-year.
- Oruka Therapeutics, Inc. costs and expenses for the quarter ending 2014-06-30 was $2.41M.
- Oruka Therapeutics, Inc. costs and expenses for the quarter ending 2014-03-31 was $2.39M.
- Oruka Therapeutics, Inc. costs and expenses for fiscal 2014 was $9.69M, a 39.67% increase from fiscal 2013.
- Oruka Therapeutics, Inc. costs and expenses for fiscal 2013 was $6.94M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 12 month |
|---|---|---|---|
| 2015-06-30 | $2.72M 10-Q · filed 2015-08-11 | $5.46M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $2.74M 10-Q · filed 2015-05-12 | ||
| 2014-12-31 | $9.69M 10-K · filed 2015-03-19 | ||
| 2014-06-30 | $2.41M 10-Q · filed 2015-08-11 | $4.80M 10-Q · filed 2015-08-11 | |
| 2014-03-31 | $2.39M 10-Q · filed 2015-05-12 | ||
| 2013-12-31 | $6.94M 10-K · filed 2015-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |